Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 2/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545309 | 0.92 | ACLY (0.50) | ACLYXIAPBIRC2KMT2AMAPT | |
| SCHEMBL17545350 | 0.92 | ACLY (0.50) | ACLYXIAPBIRC2KMT2AMAPT | |
| SCHEMBL19222362 | 0.92 | ACLY (0.50) | ACLYXIAPBIRC2KMT2AMAPT | |
| SCHEMBL19219759 | 0.88 | MAPT (0.39) | TP53KMT2AMAPTGAAMAPK1 | |
| SCHEMBL17545362 | 0.80 | KMT2A (0.46) | TP53KMT2AMAPTGAAMAPK1 | |
| SCHEMBL17545080 | 0.80 | KMT2A (0.46) | TP53KMT2AMAPTGAAMAPK1 | |
| SCHEMBL19219754 | 0.77 | XIAP (0.44) | ACLYXIAPBIRC2TP53GAA | |
| SCHEMBL19219761 | 0.76 | XIAP (0.45) | ACLYXIAPBIRC2TP53KMT2A | |
| SCHEMBL19219762 | 0.74 | ACLY (0.57) | ACLYXIAPBIRC2TP53P2RY4 | |
| SCHEMBL17545078 | 0.73 | RECQL (0.56) | ACLYXIAPBIRC2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | ACLY 1668/4885XIAP 2249/4885BIRC2 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.